A federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention. The study compared the standard five-year treatment of tamoxifen to five years of the aromatase inhibitor anastrazole in more than 3,000 DCIS survivors. The 10-year breast cancer-free survival rates were higher in the anastrazole group than in the tamoxifen group (93.5% vs. 89.2%)....

A 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC). The findings may fill a large unmet need for better treatments in this disease....

CHICAGO – Findings from four clinical trials released today at the American Society of Clinical Oncology’s (ASCO) 51^st Annual Meeting show a promising new role for immunotherapy in patients with a wide range of common, solid tumor cancers. The new study results demonstrate the effectiveness of immunotherapy drugs targeting the PD-1 protein in advanced liver, head and neck, lung, and colorectal cancers. Several of the studies also identified ...

Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumor reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months was 62%....

Findings from a randomized phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC). Among patients with advanced disease that worsened after receiving platinum-based chemotherapy, those treated with nivolumab lived on average three months longer than those treated with docetaxel chemotherapy....

A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab. This marker predicted responses across a range of cancers....

Interdiszciplináris szakmai megbeszélésre gyűltek össze reumatológus, bőrgyógyász, onkológus és immunológus szakorvosok 2014. november 11-én, Szombathelyen. A Bristol-Myers Squibb Kft. tudományos szimpóziumán elhangzó előadások az adaptív immunválasz létrejöttében közrejátszó T-sejtek aktivációját és az azt blokkoló CTLA-4 molekula működését mutatták be. A résztvevők megismerhették továbbá az ...